ABIVAX Société Anonyme (NASDAQ:ABVX) Reaches New 12-Month Low – Time to Sell?

ABIVAX Société Anonyme (NASDAQ:ABVX) reached a new 52-week low on Monday . The stock traded as low as $8.17 and last traded at $8.17, with a volume of 1567 shares. The stock had previously closed at $8.53.

ABIVAX Société Anonyme Stock Performance

The firm has a 50 day moving average of $10.00 and a two-hundred day moving average of $11.72.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Several hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. lifted its holdings in ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after buying an additional 119,300 shares in the last quarter. Walleye Capital LLC increased its position in ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after purchasing an additional 80,807 shares during the period. BNP Paribas Financial Markets raised its holdings in ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after purchasing an additional 5,900 shares during the last quarter. Finally, abrdn plc lifted its position in ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares during the period. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.